Your browser doesn't support javascript.
loading
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
Ramos, Isaac Corro; Versteegh, Matthijs M; de Boer, Rudolf A; Koenders, Jolanda M A; Linssen, Gerard C M; Meeder, Joan G; Rutten-van Mölken, Maureen P M H.
Afiliação
  • Ramos IC; Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands. Electronic address: corroramos@imta.eur.nl.
  • Versteegh MM; Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands.
  • de Boer RA; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Koenders JMA; Novartis Pharma B.V., Arnhem, the Netherlands.
  • Linssen GCM; Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, the Netherlands.
  • Meeder JG; Department of Cardiology, VieCuri Medical Centre Noord-Limburg, Venlo, the Netherlands.
  • Rutten-van Mölken MPMH; Institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands; Institute of Health Care Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
Value Health ; 20(10): 1260-1269, 2017 12.
Article em En | MEDLINE | ID: mdl-29241885

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tetrazóis / Farmacoeconomia / Modelos Econômicos / Antagonistas de Receptores de Angiotensina / Aminobutiratos / Insuficiência Cardíaca Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tetrazóis / Farmacoeconomia / Modelos Econômicos / Antagonistas de Receptores de Angiotensina / Aminobutiratos / Insuficiência Cardíaca Idioma: En Ano de publicação: 2017 Tipo de documento: Article